Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDA Reviews: Inspector General Weighs In, But Progress Depends On Congress

Executive Summary

A report by the HHS Office of Inspector General on FDA's review process for generic drugs illuminates the challenges the agency faces, but reaction to the report underscores the impression that complete resolution of the issue will require Congressional intervention
Advertisement

Related Content

Boxed Warning For Antipsychotics First Public Use Of FDA Labeling Authority
Boxed Warning For Antipsychotics First Public Use Of FDA Labeling Authority
180-Day Exclusivity Decision On Acarbose Illustrates Importance Of ANDA Quality
Teva Gets Exclusivity For Generic Kytril; FDA Still Worries About Racing, Parking
User Fee Program Renewal Gets Trickier After Ruling In Omnitrope Court Case
Advertisement
UsernamePublicRestriction

Register

PS049772

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel